Edward Garon
MD, MS
Professor
University of California, Los Angeles

Edward Garon is the Director of the Thoracic Oncology Program at the David Geffen School of Medicine at UCLA and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA. He earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His M.D. degree was from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, he was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently a Professor of Medicine. He also received a Master's degree in clinical investigation from UCLA. He has been the principal investigator of peer reviewed grants from various funding organizations including the National Institute of Health in the United States. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II and III clinical trials, including trials that have led to the approval of multiple drugs and a companion diagnostic.

Sessions

Register
General Session

Welcome

Saturday, April 27, 2024
8:00 AM - 8:05 AM
General Session

Session 1: Debate: Handling Stage 3: Surgical vs Non-Surgical Approach - DISCUSSION

Saturday, April 27, 2024
8:35 AM - 8:45 AM
General Session

Session 2: Debate: PD-L1 <1%: Is This the Place for CTLA-4 Inhibition in Lung Cancer? - DISCUSSION

Saturday, April 27, 2024
9:15 AM - 9:25 AM
General Session

Q&A

Saturday, April 27, 2024
9:55 AM - 10:05 AM
General Session

Session 4: Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - DISCUSSION

Saturday, April 27, 2024
10:55 AM - 11:05 AM
General Session

Session 6: Debate: Mesothelioma: Is There a Role for Surgery? - DISCUSSION

Saturday, April 27, 2024
1:00 PM - 1:10 PM
General Session

Session 7: Debate: ADCs: The New Emperor or the Emperor’s New Clothes? - DISCUSSION

Saturday, April 27, 2024
1:40 PM - 1:50 PM
General Session

Session 8: Debate: KRAS Inhibitors Are Standard Second-Line - DISCUSSION

Saturday, April 27, 2024
2:20 PM - 2:30 PM
General Session

Welcome

Sunday, April 28, 2024
8:40 AM - 8:45 AM
General Session

Session 9: Debate: Is There a Role for Adjuvant After Neoadjuvant Immunotherapy? - DISCUSSION

Sunday, April 28, 2024
9:15 AM - 9:25 AM